US EditionPharvaris to report phase 3 data and submit New Drug Application - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pharvaris to report phase 3 data and submit New Drug Application - Pharmafile
Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of hereditary angioedema (HAE) attacks will now be released in the fourth quarter of 2025. Pending positive results, the company expects to submit a New Drug Application to the US Food and Drug Administration in the […] The post Pharvaris to report phase 3 data and submit New Drug Application appeared first on Pharmafil…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
